Clinical Trials Browser

Fallopian Tube Diseases, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

NCT05183984 2026-04-13

NIRVANA-1

Phase 2 Recruiting

390 enrolled

Gynecologic

Ovarian Neoplasms

NCT05745857 2026-04-13

SLURP

Phase 2 Recruiting

25 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

NCT07001618 2026-04-03

IMMUNOLIFE2

Phase 2 Recruiting

162 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05733598 2026-04-02

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Phase 2 Recruiting

60 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT05854498 2026-04-02

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

Phase 2 Recruiting

50 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05769010 2026-04-01

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

Phase 2 Recruiting

150 enrolled

Breast

Breast Neoplasms

NCT04919629 2026-03-23

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Phase 2 Recruiting

60 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05489211 2026-03-19

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Phase 2 Recruiting

454 enrolled

GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05806931 2026-03-18

SCOTI

Phase 2 Recruiting

50 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT07071714 2026-03-18

A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer

Phase 2 Recruiting

200 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05231122 2026-03-16

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Phase 2 Recruiting

80 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05528952 2026-03-16

TERTIO

Phase 2 Recruiting

105 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06607458 2026-03-13

DEL-LIVER

Phase 2 Recruiting

90 enrolled

Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Phase 2 Recruiting

40 enrolled

HCC

NCT07446452 2026-03-03

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Phase 2 Recruiting

37 enrolled

Breast

HER2-low Breast Cancer

NCT01356290 2026-02-23

MEMMAT

Phase 2 Recruiting

232 enrolled

CNS

Ependymoma, Medulloblastoma, Recurrence

NCT06976944 2026-02-23

PRELUDE

Phase 2 Recruiting

44 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07407465 2026-02-17

CHIMERA

Phase 2 Recruiting

42 enrolled

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT07263438 2026-02-13

Phenix

Phase 2 Recruiting

59 enrolled

CNS

Glioblastoma, Recurrence

NCT06061809 2026-02-12

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

Phase 2 Recruiting

34 enrolled

CNS

Glioblastoma

NCT07005570 2026-01-21

Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK）

Phase 2 Recruiting

86 enrolled

Gastrointestinal

pMMR/MSS Locally Advanced Rectal Cancer

Clinical Trials

Pan Tumor Rollover Study

AndroMETa-CRC

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

PRIDE

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors

CANTOR

INTUITT-NF2

DOVE

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

JS212 Combination Therapies in Metastatic Colorectal Cancer

Kirros

CLEAR-04

New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer

A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

NIBCUN

TROY

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

NIRVANA-1

SLURP

IMMUNOLIFE2

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

SCOTI

A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

TERTIO

DEL-LIVER

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

MEMMAT

PRELUDE

CHIMERA

Phenix

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK）